Delivery Order SPE2DB22D2206-SPE2DB25FJV34
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Envarsus XR 4 mg tablets (100-count package). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open solicitation. The contract is scheduled for completion by September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,035.60 on August 5, 2025, with an ultimate completion date of August 26, 2025. The contract involves the supply of Envarsus XR 1 mg tablets in a 30-tablet quantity under firm fixed-price terms. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95 and a firm fixed-price structure. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract with a ceiling value of $1,711.95. The delivery order carries an ultimate completion date of September 4, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,151.68. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 16, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside contract, this award reflects AmerisourceBergen's capability to compete...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $1,165.05. The delivery order, classified as a non-set-aside competitive award, is scheduled for completion by September 9, 2025, with performance and delivery to occur at AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Envarsus XR 1 mg tablets (30-count package) with a ceiling value of $1,165.05. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical procurement requirements. The contract is scheduled for ultimate completion by September 18,...
- The Defense Logistics Agency awarded a $3,423.90 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages). This firm fixed price, non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs through the agency's established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $4,283.14 and an ultimate completion date of September 9, 2025. This is a firm fixed price delivery order issued under a non-set-aside competitive procurement. The award represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV34Delivery Order
The Defense Logistics Agency awarded a $10,271.70 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Envarsus XR, a tacrolimus-based immunosuppressant medication, supports critical healthcare needs for military beneficiaries, consistent with the vendor's extensive portfolio of specialty medications, brand-name and generic drugs, and other medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 9/8/25 |